Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: in-silico studies, synthesis, and biological evaluation
Neha Upadhyay, Kalpana Tilekar, Niklas Jänsch, et al.
Bioorganic Chemistry (2020) Vol. 100, pp. 103934-103934
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

2-Aminobenzothiazoles in anticancer drug design and discovery
G. Huang, Tomasz Cierpicki, Jolanta Grembecka
Bioorganic Chemistry (2023) Vol. 135, pp. 106477-106477
Closed Access | Times Cited: 29
Contribution of Knoevenagel Condensation Products toward the Development of Anticancer Agents: An Updated Review
Ramya Tokala, Darshana Bora, Nagula Shankaraiah
ChemMedChem (2022) Vol. 17, Iss. 8
Closed Access | Times Cited: 35
A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors
Anna Fontana, Ilaria Cursaro, Gabriele Carullo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 10014-10014
Open Access | Times Cited: 30
Thiazolidin-2,4-Dione Scaffold: An Insight into Recent Advances as Antimicrobial, Antioxidant, and Hypoglycemic Agents
Harsh Kumar, Navidha Aggarwal, Minakshi Gupta Marwaha, et al.
Molecules (2022) Vol. 27, Iss. 19, pp. 6763-6763
Open Access | Times Cited: 30
Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?
Sk. Abdul Amin, Samima Khatun, Shovanlal Gayen, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115594-115594
Closed Access | Times Cited: 19
Current status and future prospects of molecular hybrids with thiazolidinedione (TZD) scaffold in anticancer drug discovery
Kalpana Tilekar, Onkar Shelke, Neha Upadhyay, et al.
Journal of Molecular Structure (2021) Vol. 1250, pp. 131767-131767
Closed Access | Times Cited: 35
Synthesis, antitumor, and apoptosis-inducing activities of novel 5-arylidenethiazolidine-2,4-dione derivatives: Histone deacetylases inhibitory activity and molecular docking study
Abdelrahman Hamdi, Walaa M. El-Husseiny, Dina I. A. Othman, et al.
European Journal of Medicinal Chemistry (2022) Vol. 244, pp. 114827-114827
Closed Access | Times Cited: 23
Significance of Five-Membered Heterocycles in Human Histone Deacetylase Inhibitors
Anton Frühauf, Martin Behringer, Franz‐Josef Meyer‐Almes
Molecules (2023) Vol. 28, Iss. 15, pp. 5686-5686
Open Access | Times Cited: 16
Integrated fragment-based drug design and virtual screening techniques for exploring the antidiabetic potential of thiazolidine-2,4-diones: Design, synthesis and in vivo studies
Shankar Gupta, Gurkaran Singh Baweja, Shamsher Singh, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115826-115826
Closed Access | Times Cited: 14
Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases
Anton Frühauf, Franz‐Josef Meyer‐Almes
Molecules (2021) Vol. 26, Iss. 17, pp. 5151-5151
Open Access | Times Cited: 31
The medicinal perspective of 2,4‐thiazolidinediones based ligands as antimicrobial, antitumor and antidiabetic agents: A review
Kumari Kajal, Gurpreet Singh, Tathagata Pradhan, et al.
Archiv der Pharmazie (2022) Vol. 355, Iss. 9
Closed Access | Times Cited: 20
Overview of Class I HDAC Modulators: Inhibitors and Degraders
Ziqian Huang, Limei Zeng, Binbin Cheng, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116696-116696
Closed Access | Times Cited: 4
Thiazolidinedione derivatives: emerging role in cancer therapy
Ganesh Latambale, Kapil Juvale
Molecular Diversity (2025)
Closed Access
Permuted 2,4-thiazolidinedione (TZD) analogs as GLUT inhibitors and their in-vitro evaluation in leukemic cells
Kalpana Tilekar, Neha Upadhyay, Markus Schweipert, et al.
European Journal of Pharmaceutical Sciences (2020) Vol. 154, pp. 105512-105512
Open Access | Times Cited: 32
Pharmacophore hybridization approach to discover novel pyrazoline-based hydantoin analogs with anti-tumor efficacy
Neha Upadhyay, Kalpana Tilekar, Fulvio Loiodice, et al.
Bioorganic Chemistry (2020) Vol. 107, pp. 104527-104527
Closed Access | Times Cited: 29
Synthesis and Biological Evaluation of Pyrazoline and Pyrrolidine‐2,5‐dione Hybrids as Potential Antitumor Agents
Kalpana Tilekar, Neha Upadhyay, Franz‐Josef Meyer‐Almes, et al.
ChemMedChem (2020) Vol. 15, Iss. 19, pp. 1813-1825
Closed Access | Times Cited: 28
Thiazolidinedione “Magic Bullets” Simultaneously Targeting PPARγ and HDACs: Design, Synthesis, and Investigations of their In Vitro and In Vivo Antitumor Effects
Kalpana Tilekar, Jessica D. Hess, Neha Upadhyay, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 10, pp. 6949-6971
Closed Access | Times Cited: 26
Synthesis and in vitro antibacterial, antifungal, anti-proliferative activities of novel adamantane-containing thiazole compounds
Eman T. Warda, Mahmoud B. El‐Ashmawy, El‐Sayed E. Habib, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 18
Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects
Jinxiao Ru, Yuxi Wang, Zijia Li, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115800-115800
Closed Access | Times Cited: 10
Design, synthesis, and molecular docking studies of thiazolidinediones as PPAR‐γ agonists and thymidylate synthase inhibitors
Syed Nazreen
Archiv der Pharmazie (2021) Vol. 354, Iss. 9
Closed Access | Times Cited: 21
Matairesinol, an active constituent of HC9 polyherbal formulation, exhibits HDAC8 inhibitory and anticancer activity
Minal Mahajan, Snehal Suryavanshi, Shovonlal Bhowmick, et al.
Biophysical Chemistry (2021) Vol. 273, pp. 106588-106588
Open Access | Times Cited: 17
Exploring Thiazolidine-2,4-dione Derivatives as Privileged Scaffolds for Targeted Anticancer Agents: Biological Activity and Structure-Activity Relationship (SAR) Insights
Mayavan Viji, Gurubasavaraja Swamy Purawarga Matada, Rohit Pal, et al.
Journal of Molecular Structure (2024), pp. 140529-140529
Closed Access | Times Cited: 2
Multi-target weapons: diaryl-pyrazoline thiazolidinediones simultaneously targeting VEGFR-2 and HDAC cancer hallmarks
Neha Upadhyay, Kalpana Tilekar, Sabreena Safuan, et al.
RSC Medicinal Chemistry (2021) Vol. 12, Iss. 9, pp. 1540-1554
Open Access | Times Cited: 15
Double-edged Swords: Diaryl pyrazoline thiazolidinediones synchronously targeting cancer epigenetics and angiogenesis
Neha Upadhyay, Kalpana Tilekar, Sabreena Safuan, et al.
Bioorganic Chemistry (2021) Vol. 116, pp. 105350-105350
Closed Access | Times Cited: 15
HDAC8 As an Emerging Target in Drug Discovery With Special Emphasis on Medicinal Chemistry
S. Rajaraman, Ranjani Balakrishnan, Dhruv Deshmukh, et al.
Future Medicinal Chemistry (2023) Vol. 15, Iss. 10, pp. 885-908
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top